Study · Randomized controlled trial · n = 252 · 2011

7 results

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L

The Journal of clinical endocrinology and metabolism9 Feb 2011Cited by 340 (Europe PMC)

PMID21307137DOI10.1210/jc.2010-2081PepBankPUB-21307137

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In T2D patients, weekly exenatide reduced HbA1c more than twice-daily exenatide.
In plain wordsIn T2D patients, weekly exenatide reduced HbA1c more than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.6%
weekly
HbA1c change
−0.9%
twice daily
Source sentences
Summary
At 24 wk, ExQW produced significantly greater changes from baseline (least squares mean ± SE) vs. ExBID in HbA1c (-1.6 ± 0.1% vs. -0.9 ± 0.1%; P < 0.0001) and fasting plasma glucose (-35 ± 5 mg/dl vs. -12 ± 5 mg/dl; P = 0.0008).
3 context sentences(design, population, supporting numbers)
Summary · context
The change in HbA1c from baseline to wk 24 was measured.
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713701
02HumanRandomized controlled trialEfficacy outcome
In T2D patients, weekly exenatide reduced fasting glucose more than twice-daily exenatide.
In plain wordsIn T2D patients, weekly exenatide reduced fasting blood sugar more than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting plasma glucose change
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Fasting glucose change
−35 mg/dl
weekly
Fasting glucose change
−12 mg/dl
twice daily
Source sentences
Summary
At 24 wk, ExQW produced significantly greater changes from baseline (least squares mean ± SE) vs. ExBID in HbA1c (-1.6 ± 0.1% vs. -0.9 ± 0.1%; P < 0.0001) and fasting plasma glucose (-35 ± 5 mg/dl vs. -12 ± 5 mg/dl; P = 0.0008).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713702
03HumanRandomized controlled trialEfficacy outcome
In T2D patients, weekly and twice-daily exenatide produced similar weight reductions.
In plain wordsIn T2D patients, weekly and twice-daily exenatide produced similar weight reductions.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight change
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Weight change
−2.3 kg
weekly
Weight change
−1.4 kg
twice daily
Source sentences
Summary
Similar reductions in mean body weight from baseline to wk 24 were observed in both groups (-2.3 ± 0.4 kg and -1.4 ± 0.4 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713703
04HumanRandomized controlled trialSafety outcome
In T2D patients, weekly and twice-daily exenatide were generally well tolerated.
In plain wordsIn T2D patients, weekly and twice-daily exenatide were generally well tolerated.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableTolerability
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Outcome group
Adverse events · Pharmacology
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatments were generally well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713704
05HumanRandomized controlled trialSafety outcome
In T2D patients, nausea was less common with weekly than twice-daily exenatide and was mainly transient and mild to moderate.
In plain wordsIn T2D patients, weekly exenatide caused less nausea than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Measurements
Nausea
14%
weekly
Nausea
35%
twice daily
Source sentences
Summary
Transient and predominantly mild to moderate nausea, the most frequent adverse event, was less common with ExQW (14%) than with ExBID (35%).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713705
06HumanRandomized controlled trialSafety outcome
In T2D patients, injection-site reactions were infrequent but more common with weekly than twice-daily exenatide.
In plain wordsIn T2D patients, injection-site reactions were uncommon but more frequent with weekly than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInjection-site reactions
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Outcome group
Adverse events · Skin and wound
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Injection-site reactions were infrequent, but more common with ExQW.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713706
07HumanRandomized controlled trialSafety outcome
In T2D patients, no major hypoglycemia occurred with either exenatide regimen.
In plain wordsIn T2D patients, no major low blood sugar occurred with either exenatide regimen.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMajor hypoglycemia
Study
n = 252
Comparator
Exenatide twice daily, 5 μg for 4 weeks then 10 μg for 20 weeks
Outcome group
Adverse events · Metabolic and weight
Studied dose
2 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
No major hypoglycemia occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a 24-wk, randomized, open-label, comparator-controlled study.
Summary · context
Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.
Report a problemFND-2130713707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 3 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04431713

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

University College, Londonn = 5016 Sept 2020 to 22 Mar 2024

Multiple System Atrophy

Trial page ClinicalTrials.govUpdated 27 Jun 2025

TerminatedPhase 3NCT03419624

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Universitätsklinikum Hamburg-Eppendorfn = 1319 Feb 2018 to 5 Aug 2019

Obesity · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 31 Mar 2020

CompletedPhase 4NCT02380521

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

University of Palermon = 60Jan 2015 to Nov 2016

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 8 Nov 2016

CompletedPhase 3Results postedNCT00877890

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

AstraZenecan = 254Mar 2009 to Jan 2010

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.